Traffic Alert: Texas Medical Center road closures/water and sewer repairs. Please plan ahead and use alternate routes when possible. Learn more >

Bincy P. Abraham, MD

Fondren Distinguished Professor in Inflammatory Bowel Disease, Department of Medicine
Professor of Clinical Medicine, Academic Institute
Full Clinical Member, Research Institute
Program Director, Gastroenterology Fellowship Program, Lynda K. and David M. Underwood Center for Digestive Disorders
Houston Methodist
Weill Cornell Medical College


Biography

Bincy P. Abraham, MD, MS, is professor of clinical medicine in the Academic Division of Gastroenterology and Hepatology at Houston Methodist – Weill Cornell in Houston, Texas.

Dr. Abraham earned her undergraduate degree in bioengineering at Texas A&M University in College Station, and then received her medical degree from the University of Texas Medical Branch (UTMB) in Galveston. She completed her internal medicine internship and residency, as well as a gastroenterology fellowship at UTMB, where she also earned a master’s in clinical investigation and received specialized training in inflammatory bowel disease (IBD). During her training, she completed a National Visiting Fellow IBD Rotation Program through the Crohn’s and Colitis Foundation of America at Cedars-Sinai Medical Center in Los Angeles, California. She is board certified in Internal medicine and Gastroenterology. Dr. Abraham is a member of the American Gastroenterological Association, American College of Gastroenterology, Crohn’s and Colitis Foundation, American Society of Gastrointestinal Endoscopy, and chair of the South Texas Chapter of the Crohn’s and Colitis Foundation Medical Advisory Committee.

Description of Research

Dr. Abraham is a principal investigator and coinvestigator in several key clinical trials. As author or coauthor, Dr. Abraham’s work has been published in peer-reviewed medical journals including Clinical Gastroenterology and Hepatology, American Journal of Gastroenterology, and Inflammatory Bowel Diseases.

Areas Of Expertise

Crohn's disease Pregnancy & inflammatory bowel disease Transition of care in inflammatory bowel disease Ulcerative colitis
Publications

Role of the industry representative in the practice of gastroenterology and GI endoscopy
ASGE ARIA Committee Chair 2024, , Gastrointestinal Endoscopy. https://doi.org/10.1016/j.gie.2023.10.057

Development of Shingles on Tofacitinib Despite Completion of Recombinant Varicella-Zoster Virus Vaccine Series
Thomas, B, Moskow, J, Garza, M, Warren, B, Abraham, B & Glassner, K 2023, , ACG case reports journal, vol. 10, no. 12, pp. e01221. https://doi.org/10.14309/crj.0000000000001221

The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
Abraham, BP, Fan, C, Thurston, T, Moskow, J & Malaty, HM 2023, , Nutrients, vol. 15, no. 22, 4847. https://doi.org/10.3390/nu15224847, https://doi.org/10.3390/nu15224847

The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
Abraham, BP, Fan, C, Thurston, T, Moskow, J & Malaty, HM 2023, , Nutrients, vol. 15, no. 22, 4847. https://doi.org/10.3390/nu15224847

Real-World Impact of Infliximab Precision-Guided Dosing on Management of Patients With IBD
Abraham, BP, Ziring, DA, Dervieux, T, Han, PA, Shim, A & Battat, R 2023, , American Journal of Managed Care, vol. 29, no. 12 Suppl, pp. S227-S235. https://doi.org/10.37765/AJMC.2023.89447

The Role of Fecal Microbiota Transplantation in the Induction of Remission in Ulcerative Colitis
Saleh, A, Parsa, S, Garza, M, Quigley, EMM & Abraham, BP 2023, , Digestive Diseases, vol. 41, no. 4, pp. 656-665. https://doi.org/10.1159/000529591

Utility of Intestinal Ultrasound in Clinical Decision-Making for Inflammatory Bowel Disease
Saleh, A & Abraham, BP 2023, , Crohns and Colitis 360, vol. 5, no. 3, otad027, pp. otad027. https://doi.org/10.1093/crocol/otad027

Integrating Intestinal Ultrasound into an Inflammatory Bowel Disease Practice: How to Get Started
Abraham, BP, Reddy, D & Saleh, A 2023, , Crohns and Colitis 360, vol. 5, no. 3, otad043, pp. otad043. https://doi.org/10.1093/crocol/otad043

The Current State of Care for Black and Hispanic Inflammatory Bowel Disease Patients
Liu, JJ, Abraham, BP, Adamson, P, Barnes, EL, Brister, KA, Damas, OM, Glover, SC, Hooks, K, Ingram, A, Kaplan, GG, Loftus, EV, McGovern, DPB, Narain-Blackwel, M, Odufalu, FD, Quezada, S, Reeves, V, Shen, B, Stappenbeck, TS & Ward, L 2023, , Inflammatory bowel diseases, vol. 29, no. 2, pp. 297-307. https://doi.org/10.1093/ibd/izac124

Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease
Papamichael, K, Vande Casteele, N, Abraham, BP, Ritter, T, Jain, A & Cheifetz, AS 2023, , Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2022.10.037

Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes
Irani, M, Fan, C, Glassner, K & Abraham, BP 2023, , Clinical and Experimental Gastroenterology, vol. 16, pp. 21-28. https://doi.org/10.2147/CEG.S367086

Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease
Papamichael, K, Vande Casteele, N, Abraham, BP, Ritter, T, Jain, A & Cheifetz, AS 2023, , Clinical Gastroenterology and Hepatology, vol. 21, no. 11, pp. 2978-2980.e2. https://doi.org/10.1016/j.cgh.2022.10.037

Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease
Papamichael, K, Vande Casteele, N, Abraham, BP, Ritter, T, Jain, A & Cheifetz, AS 2023, , Clinical Gastroenterology and Hepatology, vol. 21, no. 11, pp. 2978-2980.e2. https://doi.org/10.1016/j.cgh.2022.10.037

Ustekinumab Exposure in Pregnant Women from Inflammatory Bowel Disease Clinical Trials: Pregnancy Outcomes Through Up to 5 Years in Crohn's Disease and 2 Years in Ulcerative Colitis
Abraham, BP, Ott, E, Busse, C, Murphy, C, Miller, L, Baumgart, DC, Scherl, E & Gasink, C 2022, , Crohns and Colitis 360, vol. 4, no. 3, otac025. https://doi.org/10.1093/crocol/otac025

Inflammatory bowel disease and atherosclerotic cardiovascular disease in U.S. adults—A population-level analysis in the national health interview survey
Nasir, K, Acquah, I, Dey, AK, Agrawal, T, Hassan, SZ, Glassner, K, Abraham, BP, Quigley, EMM, Blankstein, R, Virani, SS, Blaha, MJ, Valero-Elizondo, J, Cainzos-Achirica, M & Mehta, NN 2022, , American Journal of Preventive Cardiology, vol. 9, 100316. https://doi.org/10.1016/j.ajpc.2022.100316

Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium
Shen, B, Kochhar, GS, Rubin, DT, Kane, SV, Navaneethan, U, Bernstein, CN, Cross, RK, Sugita, A, Schairer, J, Kiran, RP, Fleshner, P, McCormick, JT, DHoore, A, Shah, SA, Farraye, FA, Kariv, R, Liu, X, Rosh, J, Chang, S, Scherl, E, Schwartz, DA, Kotze, PG, Bruining, DH, Philpott, J, Abraham, B, Segal, J, Sedano, R, Kayal, M, Bentley-Hibbert, S, Tarabar, D, El-Hachem, S, Sehgal, P, Picoraro, JA, Vermeire, S, Sandborn, WJ, Silverberg, MS & Pardi, DS 2022, , The Lancet Gastroenterology and Hepatology, vol. 7, no. 1, pp. 69-95. https://doi.org/10.1016/S2468-1253(21)00214-4

Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)
Abraham, B, Eksteen, B, Nedd, K, Kale, H, Patel, D, Stephens, J, Shelbaya, A, Chambers, R & Soonasra, A 2022, , Advances in Therapy, vol. 39, no. 5, pp. 2109-2127. https://doi.org/10.1007/s12325-022-02104-6

Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease
Alayo, QA, Fenster, M, Altayar, O, Glassner, KL, Llano, E, Clark-Snustad, K, Patel, A, Kwapisz, L, Yarur, AJ, Cohen, BL, Ciorba, MA, Thomas, D, Lee, SD, Loftus, EV, Fudman, DI, Abraham, BP, Colombel, JF & Deepak, P 2022, , Crohns and Colitis 360, vol. 4, no. 1, otac002, pp. otac002. https://doi.org/10.1093/crocol/otac002

Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician
Saleh, A, Ansari, U, Abughazaleh, S, Glassner, K & Abraham, BP 2022, , Biologics: Targets and Therapy, vol. 16, pp. 67-83. https://doi.org/10.2147/BTT.S335697

P013 Resolution of Infliximab Associated Infusion Hypersensitivity After Switching to Biosimilar Infliximab-dyyb
Malcolm, I, Rosalind, B, Heather, L & Bincy, A 2021, , The American Journal of Gastroenterology, vol. 116, pp. S3. https://doi.org/10.14309/01.ajg.0000798652.07957.ee